Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas

Annals of Surgical Oncology

Volumn 6, Issue 7, 1999, Pages 645-650

  Eilber, Fritz C ^a,b   Rosen, Gerald ^a   Forscher, Charles ^a   Nelson, Scott D ^a   Dorey, Frederick J ^a   Eilber, Frederick R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Intraperitoneal chemotherapy; Recurrent abdominal sarcoma

Indexed keywords

MITOXANTRONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER FAILURE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; RISK BENEFIT ANALYSIS; SARCOMA;

EID: 0032701962     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0645-8     Document Type: Article

References (24)

1. Sondak VK, Ramming KP. Sarcomas of the gastrointestinal tract. In: Eilber FR et al, eds. The Soft Tissue Sarcomas. New York: Grune & Stratton, 1987:187-204.
2. Fernandez-Trigo, Sugarbaker PH. Sarcomas involving the abdominal and pelvic cavity. Tumori 1994;79:77-91.
3. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995; 2:26-31.
4. Karakousis CP, Blumenson LE, Canavese G, Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg 1992;162:560-4.
5. Ng E-N, Pollock RE, Romsdahl MM. Prognostic implications of patters of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69:1334-41.
6. Ng E-N, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. Ann Surg 1992;215:68-77.
7. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Am J Pathol 1999;23:82-7.
8. Jereczek B, Jassem J, Kobierska A. Sarcomas of the uterus. Arch Gynecol Obstet 1996;258:171-80.
9. Akwari OE, Dozois RR, Weiland LH, Beahrs OH. Leiomyosarcoma of the small and large bowel. Cancer 1978;42:1375-84.
10. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254-61.
11. Karakousis CP, Kontzoglou K, Driscoll DL. Intraperitoneal chemotherapy in disseminated abdominal sarcoma. Ann Surg Oncol 1996;4:496-8.
12. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, Parkinson DR. Randomised comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
13. Zalupski M, Metsh B, Balcerzote S. A phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft tissue sarcoma: a Southwest Oncology Group Study. JNCI 1991;83:926-32.
14. Antman KH, Ryan L, Elias A. Response to ifosfamide and mesna in previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1984;7:126-31.
15. Mavligit GM, Zukiwski AA, Salem PA, Lamki L, Wallace S. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991;68: 321-3.
16. Mavligit GM, Zukiwiski AA, Ellis LM, Chuang VP, Wallace S. Gastrointestinal leiomyosarcoma metastatic to the liver: durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995;75:2083-8.
17. Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995;221:392-7.
18. Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in the management of soft tissue sarcomas. World J Surg 1988;12:326-31.
19. Esquivel J, Vidal-Jove J, Stevens MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631-6.
20. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622-9.
21. Smith IE. Mitoxantrone (Novantrone). a review of experimental and early clinical studies. Cancer Treat Rev 1983;10:103-15.
22. Alberts DS, Surwit EA, Peng Y-M, et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 1988;48:5874-7.
23. Alberts DS, Griffith KS, Goodman GE, Herman TS, Murray E. Phase I clinical trial of mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother Phamacol 1980;5:11-15.
24. Markman M, George M, Hakes T, et al. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 1990;8:146-50.